CONGRESS: 22–25 SEPTEMBER 2025
Mast Group
antimicrobial resistance (AMR) detection. Products such as the Mastdiscs AST range, flagship Mast Uri Connect System for UTI screening and integrated culture, and targeted kits for carbapenemase detection all contribute to efficient, evidence-based infection management. Mast’s comprehensive range of AMR tools also support surveillance and stewardship efforts, helping laboratories respond effectively to emerging resistance mechanisms. Mast’s molecular solutions support busy diagnostic laboratories with assays supporting the detection of respiratory, gastrointestinal, and genitourinary pathogens. Mast’s molecular diagnostics portfolio spans CE-marked LAMP (loop- mediated isothermal amplification) tests for rapid, targeted analysis, alongside high-throughput multiplex PCR assays for comprehensive syndromic screening. For gastrointestinal disease management, Mast provides fully automated Faecal Immunochemical Test (FIT) and calprotectin testing solutions. Utilised for bowel cancer screening as well as symptomatic testing pathways, the FIT solution delivers quantitative results with minimal manual intervention. Complementary calprotectin testing supports differentiation between inflammatory and functional bowel disorders, offering valuable insight for gastroenterology services.
www.mast-group.com
Medical Wire & Equipment Stand: 302 Medical Wire & Equipment (MWE) is delighted to be attending IBMS Congress 2025, showcasing a range of innovative products designed to support workflows in point-of-care testing, laboratory diagnostics, and infection prevention and control. MWE is committed to delivering quality across its research, manufacturing, and specimen collection solutions. Accurate results start with confident sampling, because reliable collection and transport lay the foundation for every successful diagnosis. The firm is proud to unveil the new self-collection range, developed in collaboration with healthcare
44
Medical Wire & Equipment
professionals. This range supports sampling in key areas including cancer screening, MRSA, faecal diagnostics, and respiratory infections, offering good, better, and best options for each use case. These tiered solutions provide flexibility for clinicians and empower patients with more control over their health, helping to reduce appointment backlogs and accelerate diagnostic turnaround times.
www.mwe.co.uk
Qiagen Stand: 220
Whether used for driving research or delivering critical answers to patients, Qiagen’s tools are built for reliability across both infectious diseases and oncology. The EZ2 Connect MDx system, part of Qiagen’s gold-standard sample- prep family, pairs with the QIAcuity digital PCR platform to deliver high-quality extraction and sensitive, multiplexed detection. From studying minimal residual disease to quantifying viral load, this workflow provides consistent results for research activities. In oncology, Qiagen can help you keep pace with the growing complexity of cancer research through its partnership with ID Solutions. New oncology assays available on QIAcuity deliver absolute quantification of key biomarkers for scientific research purposes. In infectious disease testing the QIAstat-Dx Analyzer and QIAstat-Dx Rise platforms offer fast, accurate syndromic testing for respiratory, GI and CNS infections, with medically relevant targets. And when it comes to tuberculosis, QuantiFERON-TB Gold Plus remains
the world’s leading IGRA test: reliable, scalable and easy to implement across care settings.
www.qiagen.com
Qpoint EQA Scheme Stand: 942
Qpoint is a point-of-care testing (POCT)- focused External Quality Assessment (EQA) scheme, managed by the POCT team at Berkshire and Surrey Pathology Services and hosted by Frimley Health NHS Foundation Trust. Established in 2005, the scheme was designed to meet the needs of healthcare staff without a scientific background, emphasising visual prompts and easy-to-understand results over complex statistics. Qpoint is a UKAS-accredited EQA
provider, offering schemes for glucose, ketones, HbA1c, urine HCG, and a multiplex respiratory panel that includes COVID-19,
Influenza A & B, and RSV. It has recently launched pilot schemes for haemoglobin and whole blood CRP, both addressing the growing
demand for POCT in hospital-at-home and community care settings.
Qpoint EQA Scheme The scheme is designed to provide
clear, one-time communication to participants. Each sample distribution includes the previous performance report, a traffic light system to explain performance, and images of devices to ensure correct identification. Drawing on the Qpoint team’s experience as an active POCT team, tailored advice on device usage is offered, including calibration for glucose meters, limitations of PCR technology, and testing modes.
www.nhsqpoint.org.uk
This preview of the IBMS Congress trade exhibition will continue in the next issue – September 2025 – featuring further exhibitors.
congress.ibms.org Qiagen AUGUST 2025
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
